One-year Survival Rate of Patients with Primary Malignant Central Nervous System Tumors after Surgery in Kazakhstan

  • Akshulakov, Serik (National Centre for Neurosurgery) ;
  • Igissinov, Nurbek (National Centre for Neurosurgery) ;
  • Aldiyarova, Nurgul (National Centre for Neurosurgery) ;
  • Akhmetzhanova, Zauresh (National Centre for Neurosurgery) ;
  • Ryskeldiyev, Nurzhan (National Centre for Neurosurgery) ;
  • Auezova, Raushan (National Centre for Neurosurgery) ;
  • Zhukov, Yevgeniy (National Centre for Neurosurgery)
  • Published : 2014.08.30


This study was conducted to evaluate the one-year survival rate of patients with primary malignant central nervous system (CNS) tumors after surgical treatment in Kazakhstan. Retrospective data of patients undergoing operations in the Department of Central Nervous System Pathology in the JSC National Centre for Neurosurgery in the period from 2009 to 2011 were used as the research material. Kaplan-Meier survival analysis was performed with the following information: gender, date of birth, place of residence, diagnosis according to ICD-10, the date of the operation, the morphological type of tumor, clinical stage, state at the end of the first year of observation, and the date of death. The study was approved by the ethical committee of the JSC National Centre for Neurosurgery. The overall one-year overall survival rate (n=152) was 56.5% (95% confidence interval (CI): 50.2-62.7), and 79.5% (95% CI 72.2-86.8) and 33.1% (95% CI: 21.0-42.3) for Grades I-II (n=76) and Grades III-IV (n=76), respectively. Significant prognostic factors which affected the survival rate were age and higher tumor grade (Grades III-IV), corresponding with results described elsewhere in the world.


Primary malignant CNS tumors;grades I-IV;Kaplan-Meier survival rate;Kazakhstan


  1. The Ministry of Health of the Russian Federation (1996). Order No. 420 "On the establishment of the State Cancer Registry." Available from: doc524a 255x165.htm. accessed on: $23.11.2013{\Gamma}$.
  2. Vaktskjold A, Lebedintseva JA, Korotov DS, et al (2005). Cancer incidence in Arkhangelskaja Oblast in Northwestern Russia. The Arkhangelsk Cancer Registry. BMC Cancer, 5, 82.
  3. WMA Declaration of Helsinki - Ethical Principles for Medical Research Involving Human Subjects. Available from: 10policies/b3, accessed on 08/01/2014.
  4. Batoroev $Y{\kappa}$ (2009). About new nosological forms of the fourth edition WHO classification of the tumours of the central nervous system (2007). Siberian Med J, 1, 5-12.
  5. Huttner A (2012). Overview of primary brain tumors: pathologic classification, epidemiology, molecular biology, and prognostic markers. Hematol Oncol Clin North Am, 26, 715-32
  6. Ohgaki H, Dessen P, Jourde B, et al (2004). Genetic pathways to glioblastoma: a population-based study. Cancer Res, 64, 6892-9.
  7. Stupp R, Hegi ME, Mason WP, et al (2009). Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomized phase III study: 5-year analysis of the EORTCNCIC trial. Lancet Oncol, 10, 459-66.
  8. Deorah S, Lynch CF, Sibenaller ZA, Ryken TC (2006). Trends in brain cancer incidence and survival in the United States: Surveillance, Epidemiology, and End Results program, 1973 to 2001. Neurosurg Focus, 20, E1.
  9. Igissinov N, Akshulakov S, Igissinov S, et al (2013). Malignant tumours of the central nervous system in Kazakhstan - incidence trends from 2004-2011. Asian Pac J Cancer Prev, 14, 4181-6.
  10. Jazayeri SB, Rahimi-Movaghar V, Shokraneh F, et al (2013). Epidemiology of primary CNS tumors in Iran: a systematic review. Asian Pac J Cancer Prev, 14, 3979-85.
  11. Lee CH, Jung KW, Yoo H, et al (2010). Epidemiology of primary brain and central nervous system tumors in Korea. J Korean Neurosurg Soc, 48, 145-52.
  12. Mehrazin M, Rahmat H, Yavari P (2006). Epidemiology of primary intracranial tumors in Iran, 1978-2003. Asian Pac J Cancer Prev, 7, 283-8
  13. Mishra MV, Andrews DW, Glass J, et al (2012). Characterization and outcomes of optic nerve gliomas: a population-based analysis. J Neurooncol, 107, 591-7.
  14. Ohgaki H, Kleihues P (2005). Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol, 64, 479-89.
  15. Sant M, Allemani C, Santaquilani M, et al (2009). EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999. Results and commentary. Eur J Cancer, 45, 931-91
  16. Smoll NR, Gautschi OP, Schatlo B, et al (2012). Relative survival of patients with supratentorial low-grade gliomas. Neuro Oncol, 14, 1062-9.
  17. Stewart LA (2002). Chemotherapy in adult high-grade glioma: a systematic review and meta- analysis of individual patient data from 12 randomised trials. Lancet, 359, 1011-8.
  18. Stupp R, Mason WP, van den Bent MJ, et al (2005). Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med, 352, 987-96.
  19. Tseng JH, Merchant E, Tseng MY (2006). Effects of socioeconomic and geographic variations on survival for adult glioma in England and Wales. Surg Neurol, 66, 258-63.
  20. Beygi S, Saadat S, Jazayeri SB, Rahimi-Movaghar V (2013). Epidemiology of pediatric primary malignant central nervous system tumors in Iran: a 10 year report of National Cancer Registry. Cancer Epidemiol, 37, 396-401.
  21. American Cancer Society (2010). Cancer Facts & Figures 2010, American Cancer Society, Atlanta. Available from: http:// statistics/cancerfacts figures2010/index, accessed on 25/10/2013.
  22. Baldi I, Gruber A, Alioum A, et al (2011). Descriptive epidemiology of CNS tumors in France: results from the Gironde Registry for the period 2000-2007. Neuro Oncol, 13, 1370-8.
  23. Cancer Registry of Norway (2012). Cancer Statistics 1953-2012, Oslo. Available from: Registries/Cancer-Statistics, accessed on 26/10/2013
  24. Central Brain Tumor Registry of the United States (2010). CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2004-2006. Source: Central Brain Tumor Registry of the United States, Hinsdale, IL. Available from: website:, accessed on 24/10/2013.
  25. Central Brain Tumor Registry of the United States (2012). Fact Sheet 2012. Central Brain Tumor Registry of the United States. Available from: factsheet/ factsheet.html, accessed on 11/01/2014
  26. Compostella A, Tosoni A, Blatt V, et al (2007). Prognostic factors for anaplastic astrocytomas. J Neurooncol, 81, 295-303.
  27. Daroff RB, Fenichel GM, Jankovich J, et al., (2012). Bradley's Neurology in clinical practice, Sixth Edition by Saunders. An imprint of Elsevier Inc. Chapter 52A, No 1107-15.
  28. Dolecek TA, Propp JM, Stroup NE, et al (2012). CBTRUS Statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. Neuro-Oncol, 14 (suppl 5), v1-v49.
  29. Ferlay J, Soerjomataram I, Ervik M, et al (2013). GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer. Available from:, accessed on 08/01/2014.
  30. Glanz S (1999). Medicobiological statistics. Moscow, 460.
  31. Gorlia T, van den Bent MJ, Hegi ME, et al (2008). Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. Lancet Oncol, 9, 29-38.
  32. Altekruse SF, Kosary CL, Krapcho M, et al (2010). SEER Cancer Statistics Review, 1975-2007: Fast Stats. Bethesdsa, MD: National Cancer Institute. Available from:, 2010, accessed on09/01/2014
  33. Louis DN, Ohgaki H., Wiestler OD, et al (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol, 114, 97-109.

Cited by

  1. Cancer Incidence and Mortality Data in Aktobe, West Kazakhstan, 2000-2010 vol.16, pp.6, 2015,
  2. Introduction of Questionnaires for Quality of Life of Patients with Malignant Tumors of the Central Nervous System into Neurosurgical Practice in the Republic of Kazakhstan vol.17, pp.2, 2016,